Strong organic revenue growth in Q4 of 13.9% and an EBIT margin of 17.2% resulted in Ambu closing the financial year within the guidance range, delivering 10.1% revenue growth and a 13.2% EBIT margin. This reflects the expected step-up in growth and profitability through 2025/26, communicated at the beginning of the financial year.
For 2026/27, Ambu expects to deliver organic revenue growth of 9.5-11.5% and an EBIT margin of 13-15%. Endoscopy Solutions will remain the key growth driver, with organic growth expected at around 15%.
“2025/26 marked the first year of our ZOOM AHEAD strategy and our journey toward global endoscopy leadership. I am encouraged by the progress we have made across our strategic priorities, advancing our innovation pipeline and customer focus, building a more scalable business platform, and developing the organization and culture needed for our next phase of growth.
We ended the year with strong momentum, delivering 13.9% organic revenue growth in Q4, driven by 21.2% organic growth in Endoscopy Solutions. This reflects broad-based momentum across all endoscopy areas and demonstrates the strength and breadth of our solutions and organization.
Looking ahead, our guidance for 2026/27 reflects our expectation of continued strong growth in Endoscopy Solutions. A key focus for the coming year will be preparing for the new product approvals across our main endoscopy areas over the next 12 to 24 months. This next wave of innovation, spanning both endoscopes and EndoIntelligence™, will further strengthen the value we bring to healthcare providers and support our journey toward achieving global endoscopy leadership.”
Britt Meelby Jensen
Chief Executive Officer
Financial highlights for Q4
Business highlights for Q4
Financial guidance 2026/27
Other notable developments in Q4: Sanne Kjærsgaard Hjordrup left Ambu as Chief People Officer on 23 October 2026, with Dorthe Rønnau stepping in as interim Chief People Officer. Dorthe most recently served as Executive Vice President of People & Culture at Coloplast.
Q4 2025/26 conference call
A conference call will be broadcast live, 5 November 2026 at 11:00 (CET), via Ambu.com/webcastQ42026. To ask questions during the Q&A session, please register prior to the call via Ambu.com/conferencecallQ42026register. Upon registration, you will receive an email with information to access the call.
The presentation can be downloaded at Ambu.com/presentations.
Company announcement no. 1 2026/27.
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,500+ Ambu team members are committed to delivering above and beyond.